Kai Lipinski, PhD, chief scientific officer of Vibalogics, a Recipharm company, focuses on oncolytic viruses (OVs); explaining how early-stage drug developers can overcome the challenges in scaling up and commercialising their products.
Erica Cohen, Greenphire, and Thomas Smith, LS public engagement specialist, explore the current issues that hinder rare disease clinical trials, and what solutions should be invested and incorporated to maximise flexibility for the trial patients.
Prof. Andy Whiting, Nevrargenics, responds to the lack of translational funding for the biotech industry, and what more needs to be done to close the gap between drug development and clinical trials.
Michael Franco, director, global biopharma sales at PSG Biotech, highlights the pain points that must be overcome in critical life science procedures and biopharmaceutical production operations.
Ahead of CPHI Japan 2023, Ian Haydock, Citeline, predicts that the continued rise of biopharma innovation in China is the big macro trend in the APAC region that could potentially lead to shifts in outsourcing and manufacturing strategies regionally.
Cem Zorlular, CEO of Er-Kim Pharmaceuticals, shares his insights on how pharma manufacturers can better navigate the global commercialisation of treatments in an ever-changing landscape.
Scientific and technological innovation is accelerating the development of effective cancer vaccines, report Drs. Daina Vanags, Cori Gorman and Christian K. Schneider of Biopharma Excellence.
Dr. Cathy Tralau-Stewart, chief scientific officer at ValiRx, describes the evolution of target validation in drug discovery, ways of tackling project attrition, and the role of human organoid models in future drug discovery strategies.
James Zaremba, sales director at automation specialist COPA-DATA, explains how specialised software can help to navigate the complexities of the new generation of smart pharmaceutical manufacturing.
Editor, Rebekah Jordan, sat down with Dr. Gen Li, president and co-founder of Phesi, to learn more about how the company’s AI-driven clinical database is allowing insights and observations to be drawn from big clinical trial data.
Vincent Guido, director of sales at Terracon, a ChargePoint Technology company, explores the challenges of fluid management in pharmaceutical manufacturing and argues that the right equipment is key to optimum efficiency, worker safety and quality.
Neil Thomas, partner and head of health care and life sciences for EMEA at Infosys Consulting, discusses the three tech-enabled R&D opportunities to drive cost-effective transformation that are still missing in the life sciences industry.
